Joshua D. Lee

MD, MSc, FASAM

Joshua D. Lee MD, MSc is an Associate Professor in the Departments of Population Health and Medicine at the NYU School of Medicine. He is board-certified in Internal Medicine and Addiction Medicine and is a physician at Bellevue Hospital Center, NYU Langone Medical Center, and in the NYC jails. He directs the NYU ABAM Fellowship in Addiction Medicine. His research focuses on novel and medication treatments for addiction among criminal justice and primary care populations.

John Rotrosen

MD

Dr. Rotrosen is Professor of Psychiatry at New York University School of Medicine. He attended NYU School of Medicine from 1968 to 1972 and completed a Psychiatry Research Residency at NYU and Bellevue Hospital in 1976. Subsequent research training was supported in part by an NIMH Research Scientist Career Development Award under the mentorship of Drs. Samuel Gershon and Burt Angrist. From 1980 through 1997, he served as Chief, Psychiatry Service, and from 1997 to 2013, as Associate Chief of Staff for Mental Health Research at the VA Medical Center in New York. His research has focused on addictive disorders, attention deficit hyperactivity disorder and schizophrenia and movement disorders, addressing pathophysiology, pharmacological and behavioral intervention, and translation to community settings. His research group has contributed to the development of many of the atypical antipsychotic agents and to the development of new medications, novel forms of medication delivery, and behavioral therapies for opiate, cocaine, alcohol and nicotine dependence. He was PI of the NY VAMC-based NIDA/VA Medications Development Research Unit from 1995-2001 and PI of the NY Node of the NIDA Clinical Trials Network (and currently one of the two PIs of the merged Greater NY Node). He recently served on the National Advisory Council on Drug Abuse (NIDA Council) and previously on NIMH Council. Current work in addictive disorders includes studies on clinical genetics, neuroimaging, medication and behavioral therapies development, implementation in mainstream healthcare settings, services and healthcare disparities, and practice improvement. He chairs and serves as a member of data monitoring and safety boards and as a medical monitor for several studies and serves as a key mentor to a multi-disciplinary group of trainees, K-awardees and junior faculty.

Edward Nunes

MD

Dr. Nunes is a Professor of Psychiatry, and Principal Investigator of the Greater New York Node of the National Institute on Drug Abuse (NIDA) clinical Trials Network as well as other NIDA funded studies on behavioral and medication treatments for substance dependence and related psychiatric disorders. Interests and ongoing studies include treatments for cocaine dependence in general, heroin and other opioid dependence, for nicotine dependence in general, and for addicted patients with co-occurring psychiatric disorders including depression, and post-traumatic stress disorder. Types of treatment under study include medication treatments (naltrexone, buprenorphine, mirtazapine) as well as behavioral and psychotherapeutic approaches and computer-delivered treatments. Dr. Nunes also studies the challenges involved in implementing evidence-based treatments for substance use disorders in real-world community-based treatments settings. Dr. Nunes also serves on the American Board of Addiction Medicine, Co-Chair of the Columbia/ New York State Psychiatric Institute's Institutional Review Board, and has been appointed to the National Advisory Council on Drug Abuse.

Lars Tanum

PhD

Lars Tanum, M.D., Ph.D., is an Associate Professor, Norwegian Centre for Addiction Research at the University of Oslo, Norway, and Head of Research Unit, Department of R&D in Mental Health Services, Akershus University Hospital, Norway. 

Sarah Wakeman

MD, FASAM

Sarah E. Wakeman, MD is the Medical Director for the Mass General Hospital Substance Use Disorder Initiative, program director of the Mass General Addiction Medicine fellowship, and an Assistant Professor of Medicine at Harvard Medical School. She is also the Medical Director of the Mass General Hospital Addiction Consult Team, co-chair of the Mass General Opioid Task Force, and clinical lead of the Partners Healthcare Substance Use Disorder Initiative. She is the Medical Director of RIZE Massachusetts, a state-wide, private sector initiative created to build a $50 million fund to implement and evaluate innovative interventions to address the opioid overdose crisis. She received her A.B. from Brown University and her M.D. from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine. She is chair of the policy committee for the Massachusetts Society of Addiction Medicine. She served on Massachusetts' Governor Baker’s Opioid Addiction Working Group. Nationally, she is chair of the American Society of Addiction Medicine Drug Court Task Force and serves on their ethics committee.Clinically she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include evaluating models for integrated substance use disorder treatment in medical settings, recovery coaching, physician attitudes and practice related to substance use disorder, and screening for substance use in primary care.

Nancy Rigotti

MD

Dr. Nancy Rigotti is a primary care physician who trained in internal medicine at Massachusetts General Hospital (MGH), where she is Associate Chief of the Division of General Internal Medicine and a Professor of Medicine at Harvard Medical School.  An internationally-known expert on tobacco use and treatment,  Dr. Rigotti has long advocated for improving the delivery of tobacco dependence treatment in the health care system.  She founded and directs MGH’s Tobacco Research and Treatment Center, which combines a clinical treatment program, the MGH Tobacco Treatment Service, with a multidisciplinary research group that develops, test, and disseminate interventions for smoking cessation across outpatient and inpatient settings.  Working at the junction of medicine and public health, Dr. Rigotti’s work combines efforts to change individual behavior with community, policy, and health care system efforts to influence individuals’ decisions about starting or continuing to smoke.

Yuchiao Chang

PhD

Dr. Chang is a statistician based in the Massachusetts General Hospital Division of General Internal Medicine. As part of this role, Dr. Chang provides biostatistical support for a number of TRTC projects. Additionally, she has collaborated on various grants with investigators from many different specialties. Dr. Chang also supports the research efforts in the Mongan Institute and is involved in many hospital operations improvement projects.

Dr. Chang participated in the Mass General Clinical Research Program from 1997 to 2001. Through this activity, she provided statistical consultation to the entire Mass General community. Over the years, Dr. Chang has provided extensive formal and informal teaching to her clinical colleagues to improve their understanding of statistical science. A great extent of her effort involves educating fellows about design and analysis issues in their research projects.

Joshua Metlay

MD, PhD

Dr. Metlay received his bachelor's degree from Yale University, his PhD in Immunology from Rockefeller University, and his MD from Cornell University Medical College.  He completed residency and chief residency in internal medicine at the University of Pittsburgh and a fellowship in general internal medicine and epidemiology at the Massachusetts General Hospital.  He also received a Master of Science in Health Policy and Management from the Harvard School of Public Health. 

Dr. Metlay's research spans two major areas, the epidemiology of drug resistance among common bacterial respiratory pathogens, particularly S. pneumoniae and the development and evaluation of interventions to improve the quality of treatment decisions for respiratory tract infections.  This research has led to numerous federal grants from NIAID, CDC, and AHRQ and roles on national advisory committees in the area of infectious diseases epidemiology.

Dr. Metlay is dedicated to education and mentorship.  He has been recognized with a number of honors including the Lindback Foundation Award for Distinguished Teaching in 2008 (Pen's highest teaching honor), the Mid-Career Research and Mentorship Award from the Society of General Internal Medicine in 2010, and the Arthur Asbury Outstanding Faculty Mentorship Award from the Perelman School of Medicine at the University of Pennsylvania in 2011. 

Michele Virva

LMSW

Michele (Shelly) Virva is a licensed master's level social worker, currently working with Dr. Corey Waller at the Spectrum Health Medical Group Center for Integrative Medicine, a specialty clinic for high frequency ED utilizers and pregnant women on controlled substances. Shelly has earned her Bachelors of Arts in political science and a Masters of Social Work from Western Michigan University. She has extensive experience in the treatment of substance use and co-occurring disorders, pregnancy and substance use disorders, crisis intervention, integrated care, and treatment of complex care patients. She has a strong interest in evidenced based treatment, research and system development. Currently, she is working with a private philanthropy in Ca. developing integrated care clinics for high opioid users. Prior to this she was part of a team working on integrating behavioral health into a multisite primary care group. She has worked with a large regional health plan in Michigan to incorporate medication assisted treatment into their benefit structure, and has co-authored the Michigan Medication Assistance Treatment Program Guidelines with Dr. Corey Waller.

Andrew Brown

MPA, MSW

Andy Brown is the Program Coordinator for the Ottawa County Recovery Court located in Michigan. He has served in this position for eight years and holds Masters Degrees in Public Administration and Social Work and is a Fellows with the National Center for State Courts. His recovery court is currently recognized as one of nine national mentor courts in the United States by the US Department of Justice and the National Association of Drug Court Professionals. Andy has a strong desire to build constructive working relationships between the courts and community partners who serve our common clientele.

Tyson Smith

PhD

No Bio Available.

Richard Saitz

MD, MPH, DFASAM, FACP

Richard Saitz MD, MPH, FACP, DFASAM is a general internist (DABIM) and primary care physician, an addiction medicine specialist (DABAM), Chair and Professor of Community Health Sciences at Boston University (BU) School of Public Health, and Professor of Medicine at BU School of Medicine. He Chaired the Treatment and Services review committee for the National Institute on Alcohol Abuse and Alcoholism, is Associate Editor of JAMA and Senior Editor of Journal of Addiction Medicine, Section Editor and sole author of key chapters in UpToDate on unhealthy substance use, an editor of the ASAM Principles of Addiction Medicine, and author of >200 peer-reviewed publications http://profiles.bu.edu/display/151440 http://www.bu.edu/sph/profile/richard-saitz/ He was Director of Boston Medical Center’s Clinical Addiction Research and Education (CARE) Unit for over a decade, has been Chairman of an Institutional Review Board, Associate Director of Clinical Research for BU, President of the Association for Medical Education and Research in Substance Abuse (AMERSA), steering committee member of the Motivational Interviewing Network of Trainers (MINT), and was coordinating committee member of International Network for Brief Intervention for Alcohol and other drug problems (INEBRIA). He is Vice President of the International Society of Addiction Journal Editors (ISAJE). His primary areas of expertise supported by NIH, RWJF, and SAMHSA, are screening and brief intervention, integrating substance-related and general health care, improving the quality of care for people with unhealthy substance use, particularly in general health settings, and basing care on science. He validated single-item screening questions recommended by NIDA and NIAAA. Awards: Alpha Omega Alpha Honor Society, Boston Jaycees Ten Outstanding Young Leaders Award, Best Doctors in America®, AMERSA’s W. Anderson Spickard, Jr. Excellence in Mentorship Award, the R. Brinkley Smithers Distinguished Scientist Award (ASAM), Research Society on Alcoholism Distinguished Researcher Award.

Darius Rastegar

MD

Dr. Rastegar provides treatment for substance use disorders in an outpatient primary care setting and an inpatient unit.  He is an Associate Professor of Medicine at Johns Hopkins University School of Medicine and is the medical director for the Chemical Dependence Unit at Johns Hopkins Bayview Medical Center.  He is the co-author of The ASAM Handbook of Addiction Medicine.

Michael Fingerhood

MD, FACP

Dr. Michael Fingerhood is an Associate Professor of Medicine at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance abuse treatment with primary medical care, including care for HIV and hepatitis C.

Gavin Bart

MD, PhD, FACP, DFASAM

Dr. Gavin Bart is Director of the Division of Addiction Medicine at Hennepin County Medical Center and Associate Professor of Medicine at the University of Minnesota. He received his MD from the University of Minnesota and trained in internal medicine at the Hennepin County Medical Center. His PhD is in experimental and clinical pharmacology, also from the University of Minnesota. He trained in addiction medicine at The Rockefeller University where he continued as Director of Clinical Research until moving to Minnesota where is is co-PI of the NorthStar Node of the NIDA Clinical Trials Network. His areas of expertise include clinical pharmacology and the pharmacological management of opioid dependence. 

His current research areas include the population pharmacokinetics of methadone, genetic influences of methadone pharmacology and treatment outcome, electronic health record privacy provisions of 42 CFR Part 2, and clinical decision support tool development for SUD. 

He is Chair of the Life-Long Learning and Self-Assessment committee for the American Board of Addiction Medicine and is ASAM Region VI (IA, IL, IN, MI, MN, WI) director. Internationally, he is co-director of the SAMHSA-funded Vietnam HIV and Addiction Technology Transfer Center and provides ongoing technical assistance for the Substance Abuse and Mental Health Administration in South East and Central Asia.

Alexander Y. Walley

MD, MSc, FASAM

Alexander Y. Walley, M.D., M.Sc., is an Associate Professor of Medicine at Boston University School of Medicine, a general internist and addiction medicine specialist at Boston Medical Center. He is the director of the Addiction Medicine Fellowship program and founded the Inpatient Addiction Consult Service at Boston Medical Center. He does clinical and research-related work on the medical complications of substance use, specifically HIV and overdose. He provides primary care and office-based buprenorphine treatment for HIV patients and methadone maintenance treatment. He is the medical director for the Massachusetts Department of Public Health’s Opioid Overdose Prevention Pilot Program. 

Lia Bennett

MPH

Lia Bennett is an independent consultant serving as the Director of Maintenance of Certification for the American Board of Addiction. She was a quality improvement program coordinator for the American College of Physicians and brings to ABAM, over 10 years of experience developing and managing MOC compliant programs. She has worked in the field of internal medicine conducting continuing medical education research in the areas of adult immunization, cardiovascular risk and diabetes. Ms. Bennett received her Masters of Public Health with a graduate certificate in Integrative Health. She strives to provide superior guidance to ABAM Diplomates.

Alain H. Litwin

MD, MPH

Alain Litwin, MD, MPH is Vice Chair of Academics and Research and Professor of Medicine at Greenville Health System, University of South Carolina School of Medicine – Greenville, and Clemson University School of Health Research where he is launching a Center for Addiction and Prevention Research.  He is board certified in internal medicine and addiction medicine, and has been providing medical care to people who use drugs with complex social, psychiatric and medical needs within an integrated primary care and substance use treatment program since 2000. As HCV Medical Director at Albert Einstein’s Division of Substance Abuse, he developed a comprehensive on-site HCV treatment program and peer educator program to improve medical care of HCV-infected people who use drugs. As HCV Treatment Network Director at Montefiore Medical Center, he expanded patient-centered models of care at many community health centers serving thousands of HCV-infected people throughout the Bronx.  With funding from NIH, PCORI, CMS, CDC, AHRQ, the Robert Wood Johnson Foundation, New York State Department of Health, New York City Department of Health, and industry, Dr. Litwin’s research has been focused on developing and studying models of HCV care, and on advocating for increasing access to effective care for all HCV-infected patients.  Dr. Litwin has worked with government and community organizations on efforts to expand access to HCV treatment and has collaborated on policy statements, clinical guidelines, treatment improvement protocols, task forces, and educational curricula with the New York City Department of Health and Mental Hygiene, New York State Department of Health, Substance Abuse and Mental Health Service Administration, Center for Substance Abuse Treatment, American Association for the Treatment of Opioid Dependence, and the American Society of Addiction Medicine.  Dr. Litwin serves on the Executive Board for the International Network on Hepatitis in Substance Users (INHSU).

Elinore F. McCance-Katz

MD, PhD

Elinore F. McCance-Katz, MD, PhD, is the first Assistant Secretary for Mental Health and Substance Use. She advises the Health and Human Services (HHS) Secretary on improving behavioral healthcare in America and leads the Substance Abuse and Mental Health Services Administration (SAMHSA), an agency responding to the nation’s opioid crisis. Dr. McCance-Katz fervently supports evidence-based early intervention, treatment, and recovery services for people who have mental health and substance use disorders. Dr. McCance-Katz has more than 25 years of experience as a clinician, teacher, and researcher.

Michael E. Charness

MD

Michael E. Charness, MD, became Chief of Staff for the VA Boston Healthcare System in 2003. His laboratory, with support from the National Institutes of Health (NIH) and the VA, studies the mechanisms of alcohol toxicity in the nervous system and the development of drugs that block alcohol toxicity. Dr. Charness is scientific director of the NIAAA-funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders, and chairs the external advisory board for the NIH-funded Adolescent Brain and Cognitive Development (ABCD) study. He has cared for patients with neurological complications of alcohol use disorder and peripheral nerve disorders throughout his career.

Judy Collins

Singer/Songwriter, Musician

Judy Collins is a modern-day renaissance woman who is also an accomplished songwriter, painter, filmmaker, record label head, musical mentor, and a high-demand speaker for mental health and addiction. She will share her story about addiction, personal triumph, how an addiction doctor helped her understand for the first time that she had a disease, and how she could get help and change her life. Ms. Collins continues to inspire audiences with sublime vocals, boldly vulnerable songwriting, and music of hope and healing that speaks to the heart.

Launette Marie Rieb

MD, MSc, CCFP, FCFP, DABAM, FASAM

Dr. Launette Rieb is a Clinical Associate Professor in the Department of Family Practice at the University of British Columbia (UBC), Canada. She is a Family Physician and diplomat of The American Board of Addiction Medicine. She did her graduate work in the area of pain physiology. She completed a postgraduate UBC Clinical Scholar's Program in 2015 and a NIDA sponsored Canadian Addiction Medicine Research Fellowship in 2016 resulting in publication on a newly described opioid pain phenomenon - withdrawal-associated injury-site pain (WISP). She has also published on fentanyl and heroin overdose deaths in BC, as well as on addiction in a variety of marginalized populations. Dr. Rieb is the Medical Director of a multidisciplinary team at OrionHealth (Vancouver Pain Clinic), and works as a consultant for the Rapid Access Addictions Clinic at St. Paul’s Hospital in Vancouver. In addition, she does addiction medicine consultations for The Orchard Recovery Centre, on Bowen Island. Dr. Rieb has taught addiction medicine in the undergraduate and postgraduate medical programs at UBC, and at national and international conferences for 24 years. Dr. Rieb was the co-creator and initial Physician Director of the St. Paul’s Hospital Goldcorp Addiction Medicine Fellowship (now the BC Centre on Substance Use Addiction Medicine Fellowship). She is a member of the Canadian Society of Addiction Medicine’s Education Committee and the College of Family Physician of Canada's Competency Creation Working Group for the Certificate of Added Competency in Addiction Medicine. Dr. Rieb is the past recipient of a UBC Faculty of Medicine Post Graduate Teaching Award. 

Peter R. Butt

MD, CCFP, FCFP

Dr. Peter Butt is a graduate of McMaster University and a Certificant and Fellow with the College of Family Physicians of Canada.  He is an Associate Professor in the Department of Family Medicine at the University of Saskatchewan in a position dedicated to Addiction Medicine, and serves as a consultant to Mental Health and Addictions in the Saskatoon Health Region.  National committee work includes the National Alcohol Strategy Advisory Committee, chair of the Canadian Alcohol Low Risk Drinking Guidelines Expert Advisory Group, co-chair of the Standard Drink Label Working Group, and member of the National Recovery Advisory Committee for the Canadian Centre on Substance Abuse; and physician lead on the Alcohol Screening, Brief Intervention and Referral project for the College of Family Physicians of Canada.  Provincially he is the physician lead on the Saskatchewan provincial “Take Home Naloxone”project, chairs the Opioid Advisory Committee for the College of Physicians and Surgeons of Saskatchewan, and serves on the Health Canada - First Nation Prescription Drug Abuse Initiative.

Deidra Y. Roach

MD

Dr. Roach has more than 30 years of experience in the field of addiction treatment. She currently serves as a Program Director for the National Institute on Alcohol Abuse and Alcoholism where, among other responsibilities, she manages research portfolios addressing the treatment of co-occurring mental health and alcohol use disorders and alcohol-related HIV/AIDS among women. She also serves on the Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) and the NIH Coordinating Committee for Research on Women’s Health. Dr. Roach chairs the Women Drinking, and Pregnancy Work Group of the ICCFASD.

Scott H. Stewart

MD, MS

Scott H. Stewart, MD, MS, Associate Professor, Division of General Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo. 

Dr. Stewart is a general internist and adult primary care physician, currently teaching and practicing at the Erie County Medical Center, an academic urban safety-net hospital in Buffalo, NY.   After graduating medical school at Temple University in 1993 and completing Internal Medicine training at the University of Pittsburgh in 1996,Dr. Stewart worked for three years in private practice in the beautiful state of Maine, then returned to academia and completed a health services research fellowship at MUSC in Charleston, SC. He has been on the faculty of MUSC and the University at Buffalo since 2001. Working with experienced mentors at the Charleston Alcohol Research Center at MUSC and Research Institute on Addictions in Buffalo early in his research career helped in melding his long-standing interest in alcohol-related problems with scholarly efforts, leading to NIAAA support. 

Dr. Stewart believes that objective testing and monitoring is needed to optimize AUD treatment in primary care, similar to other chronic conditions such as diabetes and dyslipidemia. While traditional alcohol consumption biomarkers suffer from limited sensitivity or specificity, and self-report screens are subject to error, relatively newer biomarkers have great potential to guide AUD treatment. Accordingly, a point of my foci has been on the use of carbohydrate-deficient transferrin and newer biomarkers (e.g., blood phosphatidylethanol, ethyl glucuronide) in various patient populations and during alcoholism treatment trials. Dr. Stewart believes biomarker development is a complicated and slow process, but these and other laboratory tests will continue to alter how AUD is detected and monitored in medical settings in the coming years.

Judith Hahn

PhD

Judy Hahn, PhD is an Associate Professor in the HIV, ID, and Global Medicine Division in the Department of Medicine at UCSF. She is an epidemiologist with extensive experience studying the behavioral and biological intersections of substance use and infectious diseases. She is a pioneer in the use of biological markers as objective measures for alcohol use. She has received numerous grant awards from the NIH and has published over 100 manuscripts. 

She is currently leading studies to examine the safety and cost-benefit ratios of using isoniazid to prevent active TB among HIV/TB co-infected drinkers in Uganda, interventions to improve the safety of INH delivered to this population, as well as using mobile phones and tablets to reduce the harm associated with heavy alcohol use. Judy is also a long-time investigator on the UFO Study of HCV in young persons who inject drugs in San Francisco.

M. Katherine Jung

PhD

M. Katherine Jung, PhD, is the Director of the Division of Metabolism and Health Effects (DMHE) in the National Institute on Alcohol Abuse and Alcoholism (NIAAA). DMHE oversees a portfolio on the role of alcohol on organ damage, and the mechanisms of alcohol’s effect on physiology and pathology. Dr. Jung’s training and research experience are in biochemistry, cell biology, and molecular biology. Her peer-reviewed publications span the the areas of alcohol-induced organ damage, cell biology, cancer biology, and drug discovery. She has a longstanding interest in biomarkers of alcohol consumption and of alcohol-associated organ damage. Dr. Jung co-leads the Wearable Alcohol Biosensor initiative for NIAAA.

JoAn Laes

MD

JoAn Laes, MD, Attending Physician, Division of Addiction Medicine, Hennepin County Medical Center, Minneapolis, MN; Core Medical Toxicology Faculty, Minnesota Poison Control System, Minneapolis, MN; Medical Director, Mission Detox Center, Plymouth, MN and 1800 Detox, Minneapolis, MN, ASAM Medical Toxicology workgroup Chair.Dr. Laes' practice is focused on inpatient addiction medicine and toxicology consultation and outpatient treatment of opioid and other substance use disorders. She is board certified in Internal Medicine, Addiction Medicine, and Medical Toxicology. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.

Christine Murphy

MD

Dr. Christine Murphy is an Associate Professor in Emergency Medicine and Medical Toxicologist at Carolinas Healthcare System in Charlotte, North Carolina. Dr. Murphy is the Director for the Medical Toxicology Fellowship Program. She received both her bachelor’s and master’s degrees in chemistry from the College of William and Mary and her medical degree from the Medical College of Virginia. She completed her residency training in Emergency Medicine at Virginia Commonwealth University and a fellowship in Medical Toxicology at Carolinas Medical Center. Dr. Murphy is board certified in Emergency Medicine, Medical Toxicology, and Addiction Medicine. Her current research interests include alternative uses for existing antidotes, pediatric addiction, and trends in recreational drugs of abuse.

Matthew Peter Stripp

MD

Dr. Matthew Stripp is a Junior Faculty Member in Emergency Medicine and a Medical Toxicology Fellow at Carolinas Healthcare System in Charlotte, NC. He received his BA in Cell/Molecular Biology with an emphasis in Neuroscience at Washington & Jefferson College in Washington, PA. He received his medical degree at Temple University School of Medicine in Philadelphia, PA. He completed his residency training in Emergency Medicine at Northwell Health in Manhasset, NY. Dr. Stripp is board certified in Emergency Medicine. His current research interests include mushroom toxicity, synthetic cannabinoids, and other emerging drugs of abuse.